Framing: examine incentives alongside clinical independence and patient choice. HHS OIG’s telemedicine fraud alert identifies volume-linked practitioner compensation and constrained treatment choices among suspect characteristics. Its federal analysis concerns particular arrangements and federal healthcare-program exposure; it is not a blanket legal conclusion about every self-pay service fee. (oig.hhs.gov)
Put to: Jesse Dresser and Robert Kushner.
Buyer owner: Counsel, medical director and CFO.
Why it matters: The clinic should understand whether commercial incentives affect prescribing, pharmacy selection or patient communications before those incentives become embedded in growth targets.
A good answer should cover:
- Every payment, discount, rebate, marketing contribution and ownership interest.
- Whether compensation depends on prescriptions, fills, medicine selection or continued use of a particular partner.
- The actual services delivered and the evidence supporting their valuation.
- Relevant federal and state analyses for the proposed facts—not an unsupported assurance that ‘cash-pay means exempt’.
- Clinical discretion and the process for supporting a different clinically appropriate route.
Follow-up that tests the answer: “Would the economics still work if the clinician declined to prescribe or the patient selected another pharmacy?”
Evidence to request: A complete remuneration schedule, conflict disclosures and arrangement-specific legal review. Apply the same transparency standard to research sponsorships and supplier introductions.
Expert quote — reserved: ________________________________________
Sources cited on this page
- oig.hhs.gov · Source 1 ↗https://oig.hhs.gov/documents/root/1045/sfa-telefraud.pdf